CEVEC: CAPĀ® Derived Recombinant C1 Inhibitor Matches BerinertĀ® in Animal Study

Cologne, Germany, February 2, 2015
CEVEC Pharmaceuticals, the developer and licensor of the CAP® Technology, today announced a major milestone regarding its recombinant human CAP® cell derived C1 Esterase Inhibitor (C1Inh).

CEVEC´s CAP derived C1 Inhibitor material showed in a pivotal pharmacokinetic rat study a serum half life matching one of the two currently available, plasma derived treatments, Berinert®. All other known versions of recombinant C1 Inh, including e.g. Ruconest® from transgenic rabbits, displayed so far a significantly shorter half life than plasma derived C1 Inh. To achieve this excellent protein quality of the recombinant C1Inh, new glycosylation optimized CAP-GO cells were developed at CEVEC. This result, in combination with previously shown excellent specific activities of CAP derived C1 Inh and commercially attractive production yields using CAP-GO cells, paves now the way to develop a safer and more economic therapy for acute and prophylactic HAE indications.

CAP for Protein Production

Proteins

CAP and CAP-T Cells exhibit exceptional yields for complex proteins and antibodies. Authentic human-like post-translational modifications allow for higher specific activities and more cost-effective large scale productions of therapeutic molecules. A unique advantage of the transiently protein producing CAP-T Cells and the stably producing CAP Cells are identical and highest product qualities provided by an isogenic cellular background.

> READ MORE

CAP for Vaccine Production

Vaccines

CAP Cells exhibit key advantages in the field of vaccine development: adapted to animal component free suspension culture the human amniocyte derived cells propagate a very broad range of clinically relevant human viruses at high titers. Non-tumorous origin, development of the cell line under guidance of ethical advisory committees and a fully documented history from donor to Master Cell Bank position CAP as a versatile mammalian expression host.

> READ MORE

Clinical Material

cGMP

CEVEC is your contract manufacturer of choice for cGMP production in CAP Cells.
CAP-derived clinical material can be provided for phase I-II studies and we produce your desired protein, vaccine, virus or gene therapy vector at extraordinary pace and competitive pricing through our CAP CMO Joint Venture with Genibet in Lisbon/Portugal.

> READ MORE